PerVision
Prospective phase I/II trial of an individualized peptide vaccine in pediatric and AYA patients with metastasized fusion-driven sarcomas following standard treatment
Recruiting
Summary
The trial in pediatric, adolescent and young adult patients with metastasized fusion-driven sarcomas following standard treatment aims to assess the T-cell response induced by individualized fusion-petide and neopetide vaccination.
The trial will include patients with so called "fusion-driven", metastatic sarcomas of the following types:
- Ewing sarcoma,
- alveolar rhabdomyosarcoma
- or synovial sarcoma
who are in first or second complete remission or partial response.
Main inclusion criteria
- Age ≥ 2 to < 40 years
- Confirmed metastatic fusion-driven sarcoma (rhabdomyo-, Ewing- and synovial sarcoma) in first or second complete remission (CR) or partial response (PR) after first therapy phase
- Access to whole exome sequencing and RNAseq data of the gene fusion
- Successful design and production of the patient-individual vaccine cocktail
Sponsor
University Hospital Tuebingen